Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resmetirom Safety and Biomarkers in NAFLD (MAESTRO-NAFLD-1)
NCT04197479Phase 3Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of resmetirom in non-alcoholic fatty liver disease (NAFLD), Nonalcoholic steatohepatitis (NASH), Nonalcoholic Steatohepatitis Cirrhosis, sponsored by Madrigal Pharmaceuticals. Started Dec 2019; status: completed.
02
Drugs
resmetirom
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Nonalcoholic steatohepatitis (NASH)Nonalcoholic Steatohepatitis Cirrhosis
Beyond the preview
Go deeper on NCT04197479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04197479.